This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1999 Aug 4;91(15):1281-7.

doi: 10.1093/jnci/91.15.1281.

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

K A Gelmon¹, E A Eisenhauer, A L Harris, M J Ratain, P Workman

Affiliations

PMID: 10433616
DOI: 10.1093/jnci/91.15.1281

Review

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?

K A Gelmon et al. J Natl Cancer Inst. 1999.

. 1999 Aug 4;91(15):1281-7.

doi: 10.1093/jnci/91.15.1281.

Authors

K A Gelmon¹, E A Eisenhauer, A L Harris, M J Ratain, P Workman

Affiliation

¹ British Columbia Cancer Agency, Vancouver, BC, Canada. kgelmon@bccancer.bc.ca

PMID: 10433616
DOI: 10.1093/jnci/91.15.1281

No abstract available

PubMed Disclaimer

Comment in

Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents.
Korn EL. Korn EL. J Natl Cancer Inst. 2004 Jul 7;96(13):977-8. doi: 10.1093/jnci/djh208. J Natl Cancer Inst. 2004. PMID: 15240771 No abstract available.

Similar articles

Development of investigational radiation modifiers.
Colevas AD, Brown JM, Hahn S, Mitchell J, Camphausen K, Coleman CN; Radiation Modifier Working Group of the National Cancer Institute. Colevas AD, et al. J Natl Cancer Inst. 2003 May 7;95(9):646-51. doi: 10.1093/jnci/95.9.646. J Natl Cancer Inst. 2003. PMID: 12734315 Review. No abstract available.
Novel agents in colorectal cancer.
Erlichman C. Erlichman C. Tumori. 2001 Jan-Feb;87(1 Suppl 1):S9. Tumori. 2001. PMID: 11300041 No abstract available.
OSI-461 (OSI).
Galmarini CM. Galmarini CM. Curr Opin Investig Drugs. 2004 Jun;5(6):648-56. Curr Opin Investig Drugs. 2004. PMID: 15242254 Review.
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK. Rowinsky EK. J Clin Oncol. 2003 May 15;21(10 Suppl):175s-186s. doi: 10.1200/JCO.2003.01.146. J Clin Oncol. 2003. PMID: 12743132 Review.
Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.
Jäger T, Ocker M, Kiesslich T, Neureiter E, Neureiter D. Jäger T, et al. Expert Opin Investig Drugs. 2017 Feb;26(2):133-136. doi: 10.1080/13543784.2017.1274392. Epub 2016 Dec 27. Expert Opin Investig Drugs. 2017. PMID: 28004600 No abstract available.

See all similar articles

Cited by

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key.
de Bono JS, Tolcher AW, Rowinsky EK. de Bono JS, et al. Breast Cancer Res. 2003;5(3):154-9. doi: 10.1186/bcr597. Epub 2003 Mar 27. Breast Cancer Res. 2003. PMID: 12793897 Free PMC article. Review.
Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin.
Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO. Liu D, et al. Br J Cancer. 2002 Sep 23;87(7):783-9. doi: 10.1038/sj.bjc.6600558. Br J Cancer. 2002. PMID: 12232764 Free PMC article.
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.
Ferte C, Soria JC, Penel N. Ferte C, et al. PLoS One. 2011 Mar 2;6(3):e16633. doi: 10.1371/journal.pone.0016633. PLoS One. 2011. PMID: 21415927 Free PMC article.
Balancing safety, effectiveness, and public desire: the FDA and cancer.
Conti R. Conti R. Issue Brief (Commonw Fund). 2003 Apr;(615):1-6. Issue Brief (Commonw Fund). 2003. PMID: 12693391 Free PMC article. No abstract available.
The changing face of phase 1 cancer clinical trials: new challenges in study requirements.
Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. Craft BS, et al. Cancer. 2009 Apr 15;115(8):1592-7. doi: 10.1002/cncr.24171. Cancer. 2009. PMID: 19165808 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database